Maryland-based medical device startup CarrTech Corp. has raised $750,000 in a recent funding round, bringing its total lifetime funding to nearly $2.2 million. The investment includes $250,000 from the Maryland Technology Development Corp. and matching funds from existing investor Old Line Capital Partners. CarrTech plans to utilize the funds to submit their product, a filter needle for administering liquid drugs, to the FDA by early fall.
It's already on there. You're not having really to manipulate the ampule much more than the first time that you're doing it. And you're not having to take one needle, open it up to set it down, taking one-off, set it down, and put the other one on. So to me, it solves all the problems that exist within the aspects of sterile compounding or sterile IDs."
Dr. John Kutzko, PharmD
Compound Pharmacy Owner
The company aims to provide a safer and more efficient alternative to existing products on the market. CarrTech's strategic partner, a leading needle manufacturer, is expected to aid in obtaining FDA approval, anticipated in the first half of 2024. Their patented FROG product combines injection and filter mechanisms to simplify the process and reduce risks associated with contamination and delays in treatment.
Sue Fisher Carr - Founder/President
Sue Carr is president and founder of CarrTech LLC. CarrTech is a medical device company that is currently developing FROG™, Filter Removal of Glass which is an all in one package, one needle and filter, that is safer, quicker, easier, and a greener solution.